# Overexpression of KMT9α is associated with poor outcome in cholangiocarcinoma patients

**Authors:** Maximilian N. Kinzler, Eric Metzger, Rebecca Schulz, Katrin Bankov, Anna Ramos-Triguero, Falko Schulze, Steffen Gretser, Nada Abedin, Armin Wiegering, Stefan Zeuzem, Dirk Walter, Henning Reis, Roland Schüle, Peter J. Wild

PMC · DOI: 10.1007/s00432-025-06214-w · Journal of Cancer Research and Clinical Oncology · 2025-05-13

## TL;DR

Overexpression of the KMT9α protein is linked to worse survival in cholangiocarcinoma patients and could be a new target for treatment.

## Contribution

This is the first study to investigate KMT9α in cholangiocarcinoma and its association with survival outcomes.

## Key findings

- 35.1% of cholangiocarcinoma patients overexpress KMT9α, which is associated with shorter overall survival.
- KMT9α overexpression is an independent risk factor for poor survival in cholangiocarcinoma.
- KMT9α expression varies significantly across cholangiocarcinoma subtypes.

## Abstract

The newly discovered histone methyltransferase KMT9 serves as an epigenetic regulator of carcinogenesis in various cancer entities. For the first time, we investigated the presence of KMT9α in cholangiocarcinoma, the association with histologic subtypes, and its impact on survival.

A tissue microarray cohort of all CCA patients who underwent surgical resection with curative intent between 08/2005 and 12/2021 at the University Hospital Frankfurt was immunohistochemically analyzed with the KMT9α antibody. For overall survival, Kaplan–Meier curves and Cox-regression analyses were performed.

In total, 174 patients were suitable for IHC analysis. Of the patients, 35.1% (n = 61) overexpressed KMT9α. Kaplan-Meier curves revealed a median OS of 34.75 months (95% CI = 20.23–49.27 months) for all CCA patients positive for KMT9α in comparison to 54.21 months (95% CI = 41.78–66.63 months) for patients lacking KMT9α overexpression (p = 0.004). Subtype analysis revealed strong differences in KMT9α expression. Multivariate Cox regression analysis identified KMT9α as an independent risk factor for shorter OS in CCA.

This study demonstrates that a marked subset of CCA patients exhibit overexpression of KMT9α. These findings underscore the prognostic significance of KMT9α and reinforce its potential as a therapeutic target, consistent with its role in other cancer types.

The online version contains supplementary material available at 10.1007/s00432-025-06214-w.

## Linked entities

- **Diseases:** cholangiocarcinoma (MONDO:0019087)

## Full-text entities

- **Genes:** PRDM9 (PR/SET domain 9) [NCBI Gene 56979] {aka KMT8B, MEISETZ, MSBP3, PFM6, ZNF899}
- **Diseases:** carcinogenesis (MESH:D063646), cancer (MESH:D009369), CCA (MESH:C536211), cholangiocarcinoma (MESH:D018281)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12069507/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12069507/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12069507/full.md

---
Source: https://tomesphere.com/paper/PMC12069507